Related Experiment Video
Updated: Jun 28, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
A Ruthenium-BODIPY Photosensitizer for Light-Triggered Apoptosis in Triple-Negative Breast Cancer Cells.
Ting-Hsuan Wang1, Chia-Hsuan Lin2, Eng Zhi Sim2
1School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.
Inorganic Chemistry
|June 26, 2026
Summary
This study introduces RuB3, a novel photodynamic therapy (PDT) agent. RuB3 selectively induces apoptosis in breast cancer cells upon light activation, showing promise for targeted cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Photochemistry
Background:
- Selective activation of therapeutic agents in the tumor microenvironment is crucial for improving cancer treatment efficacy and safety.
- Photodynamic therapy (PDT) offers a targeted approach by activating photosensitive drugs with light.
- Developing novel PDT agents with minimal off-target effects is an ongoing area of research.
Purpose of the Study:
- To introduce and evaluate RuB3 as a novel agent for photodynamic therapy (PDT).
- To investigate the potential of RuB3 to selectively induce apoptosis in MDA-MB-231 breast cancer cells.
- To confirm the light-dependent functionality of RuB3 as a PDT agent.
Main Methods:
- Utilized live cell imaging techniques.
- Employed fluorescence microscopy.
- Conducted flow cytometry analysis.
Main Results:
- Demonstrated that RuB3 facilitates targeted reactive oxygen species (ROS) generation upon light activation.
- Showcased RuB3's ability to induce apoptotic pathways in cancer cells.
- Observed a significant, light-dependent increase in apoptotic effects, confirming RuB3's PDT functionality.
Conclusions:
- RuB3 functions as an effective photodynamic therapy agent.
- RuB3 exhibits potent efficacy and minimal off-target effects in MDA-MB-231 breast cancer cells.
- RuB3 represents a promising advancement for targeted PDT approaches in cancer therapy.
